Study on the Improvement of Neurological Function by Astragalus Injection Combined with Transcutaneous Electrical Acupoint Stimulation in Patients After Traumatic Intracerebral Hemorrhage Surgery

Start Date30 Jul 2025

Sponsor / Collaborator-

ITMCTR2024000722

/ SuspendedIIT

Professor Deng Tietao a master of traditional Chinese medicine conducted a clinical efficacy and mechanism study on the Astragalus and Ephedra Formula in different dosage forms for the stable period of threshold in patients with bradyarrhythmia after pacemaker implantation.

Start Date01 Dec 2024

Sponsor / Collaborator-

ITMCTR2024000197

/ SuspendedNot ApplicableIIT

A study on the clinical efficacy of Ginseng-Astragalus Delayed Failure Formula in treating frailty syndrome in the elderly

Start Date18 Aug 2024

Sponsor / Collaborator

Xiyuan Hospital of China Academy of Chinese Medical Sciences

100 Clinical Results associated with Astragalus polysaccharide

100 Translational Medicine associated with Astragalus polysaccharide

100 Patents (Medical) associated with Astragalus polysaccharide

217

Literatures (Medical) associated with Astragalus polysaccharide

01 Jan 2027·JOURNAL OF ETHNOPHARMACOLOGY

Astragalus polysaccharides ameliorate irinotecan-induced gut toxicity by regulating gut microbiota and suppressing the MAPK signaling

Article

Author: Zeng, Hairong ; Chen, Lu ; Liu, Wei ; Zhang, Linzhang ; Xu, Chuting ; Zhou, Chenyang ; Wu, Bolin ; Wu, Jianjun ; Chen, Senjie ; Ge, Guangbo

ETHNOPHARMACOLOGICAL RELEVANCE:

Astragalus membranaceus var. mongholicus (Bunge) P.K.Hsiao (AM), a classic Qi-tonifying herb, has been widely used for treating a range of inflammatory diseases. Nevertheless, the protective effects of AM against irinotecan-induced gut toxicity (IGT) remains insufficiently characterized, while the active pharmacological fractions and the underlying anti-IGT mechanisms have not been fully elucidated.

AIMS:

This study aimed to investigate the ameliorative effects of the water extract of AM and its fractions on IGT in mice, as well as to identify the most potent anti-IGT fraction and to reveal the underlying anti-IGT mechanisms.

METHODS:

The water extract of AM (WEA) was administered to an IGT murine model. Therapeutic efficacy was assessed using the Disease Activity Index (DAI), while histopathology was evaluated via H&E and PAS staining. Intestinal barrier integrity was examined by measuring ZO-1, Occludin, and Muc2 expression using RT-qPCR, immunofluorescence, and immunohistochemistry. Colonic pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) were quantified by ELISA. Following confirmation of efficacy, four fractions were isolated and compared. The most effective fraction, Astragalus membranaceus polysaccharides (APS), was further investigated using 16S rRNA sequencing, microbial metabolomics, transcriptomic, and Western blot.

RESULTS:

APS significantly improved body weight loss and reduced DAI in IGT mice. H&E staining showed that APS ameliorated structural damage and inflammatory infiltration in colonic tissues. PAS staining revealed a notable increase in goblet cell numbers following APS treatment. RT-PCR and immunohistochemical staining confirmed that APS enhanced the expression of intestinal barrier markers (ZO-1, Occludin, Muc2) and promoted crypt proliferation (Ki67) in colonic tissue. Consequently, APS markedly reduced the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in colonic tissues from IGT mice. 16S rRNA sequencing showed that APS regulated gut microbiota composition, thereby increasing the beneficial metabolites (e.g. butyrate acid) in colonic lumen. It was also found that APS significantly reduced the abundance of gmβ-GUS-producing bacteria, which in turn, decreasing gmβ-GUS enzymatic activity and the intestinal exposure levels of the toxic metabolite SN-38. Finally, transcriptomic analysis of colonic tissues revealed that APS suppressed the MAPK signaling pathway (MEK, ERK, P38, JNK) and down-regulated apoptosis-related genes (Bax, Bcl-2) in IGT mice.

CONCLUSION:

Our findings suggest that APS, the key active fraction of AM against IGT, mitigate IGT by modulating microbiota-metabolite-MAPK axis, offering novel mechanistic insight for the ethnopharmacological use of AM to mitigate chemotherapy-induced intestinal toxicity.

31 Dec 2026·ANNALS OF MEDICINE

Ceftriaxone for methicillin-susceptible Staphylococcus aureus bloodstream infections is associated with increased short-term mortality: a systematic review and meta-analysis

Review

Author: Maraolo, Alberto Enrico ; Nobile, Mariano ; Gentile, Ivan

BACKGROUND:

Bloodstream infections (BSIs) by methicillin-susceptible Staphylococcus aureus (MSSA) are a significant cause of morbidity and mortality, traditionally treated with antistaphylococcal penicillins (ASPs) or cefazolin. Ceftriaxone has emerged as an alternative due to its once-daily dosing regimen and favourable safety profile; however, its efficacy compared to the standard of care (SoC) remains controversial. This evidence synthesis aimed to assess the role of ceftriaxone in treating MSSA-BSIs.

METHODS:

A systematic literature search was conducted in PubMed, Embase, and Scopus up to December 31, 2025 (PROSPERO protocol CRD42024595748). Studies comparing ceftriaxone to ASPs or cefazolin for MSSA-BSIs were included. Primary outcomes were 30-day and 90-day all-cause mortality . Pooled effect sizes with their 95% confidence intervals (CIs), were calculated using random-effects models, odds ratios (ORs) and mean differences (MDs) according to the type of outcome.

RESULTS:

Eleven studies totalling 2,568 patients were included. Ceftriaxone was associated with significantly increased 30-day mortality (OR 3.33; 95% CI: 2.17-5.10), although differences at 90 days were not significant (OR 1.71; 95% CI: 0.75-3.90). No significant differences were noted for clinical success (OR 0.49; 95% CI: 0.19-1.26), microbiological clearance (OR 1.66; 95% CI: 0.73-3.82). Adverse event rates were similar between groups.

CONCLUSION:

Given the availability of various alternatives and the consistent short-term mortality signal observed, routine use of ceftriaxone for MSSA-BSIs, especially as initial therapy, is not supported by current evidence. Only novel findings from randomized studies may change the place in therapy of the drug in this context.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Therapeutic effects of 1,25-dihydroxyvitamin D3 with astragalus polysaccharide on insulin resistance in gestational diabetes mellitus rat models

Article

Author: Qu, Jiayuan ; Wang, Yuhong ; Li, Wenjian ; Yan, Shuqi ; Pan, Qizheng ; Ren, Shuping ; Tan, Chong ; Ma, Haoyan ; Wei, Ming

BACKGROUND:

Approximately 9 to 26% of pregnant individuals develop gestational diabetes mellitus (GDM), for which insulin resistance is a key driver. 1,25-dihydroxyvitamin D (1,25(OH)₂D₃) and astragalus polysaccharide (APS) can each alleviate insulin resistance, yet their combined mechanisms remain poorly elucidated.

METHODS:

Diabetic rats were induced by high-fat diet and low-dose streptozotocin in Sprague-Dawley rats, then treated with 1,25(OH)₂D₃, APS, or both for two weeks. Serum glucose, insulin, and lipid profiles were measured. In the liver, reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD) activity, liver function markers, and protein expression of vitamin D receptor (VDR), insulin signaling, PI3K/AKT/FOXO1, gluconeogenesis, and lipid metabolism pathways were assessed. Co-immunoprecipitation was also performed to examine VDR-PI3K p85 interaction.

RESULTS:

In GDM rats, combined 1,25(OH)₂D₃ and APS intervention significantly reduced the serum levels of glucose, aspartate aminotransferase, alanine aminotransferase, free fatty acid, triglyceride and apolipoprotein B, and homeostatic model assessment of insulin resistance(p < 0.05). The combination decreased hepatic ROS and MDA levels, increased hepatic SOD activity, upregulated VDR and cytochrome P450 2R1 mRNA levels, and increased the protein expression levels of VDR, insulin receptor, insulin receptor substrate 1, glucose transporter 2, PI3K, AKT, pAKT and the pAKT/AKT ratio (p < 0.05). It also suppressed the protein expression levels of FOXO1, PEPCK, G6pase and SREBP1C, and increased PPARγ levels (p < 0.05). Co-immunoprecipitation assay confirmed a potential interaction between VDR and PI3K p85 in liver tissues.

CONCLUSION:

Combined 1,25(OH)₂D₃ and APS alleviated insulin resistance and metabolic disorders in GDM rats, possibly via VDR upregulation, oxidative stress attenuation, and PI3K/AKT/FOXO1 signaling modulation.

News (Medical) associated with Astragalus polysaccharide

02 Oct 2026

·www.prnewswire.com

PhytoHealth CEO Angel Lee Recognized for Driving the Advancement of World's First Prescription Drug for Cancer-Related Fatigue

Recognition highlights PhytoHealth's work in advancing PG2®, Taiwan's first approved botanical new drug, and raising clinical awareness of cancer-related fatigue TAIPEI, Oct. 2, 2026 /PRNewswire/ -- PhytoHealth Corporation CEO Angel Lee has been named one of Taiwan's 27th Ten Outstanding Young Women. The prestigious national recognition highlights her leadership in advancing PG2® Lyo. Injection—the world's first prescription drug approved specifically for moderate to severe cancer-related fatigue (CRF)—and her contributions to botanical drug development and cancer supportive care. Continue Reading PhytoHealth Corporation CEO Angel Lee at the company’s headquarters in Taiwan. Photo: Hsiao Peng-Kai / Business Today Developed from refined polysaccharides of Astragalus membranaceus, a medicinal plant documented in the WHO Monographs on Selected Medicinal Plants, PG2® is also Taiwan's first approved botanical new drug. PG2® is used across medical institutions in Taiwan for the management of cancer-related fatigue and is covered by Taiwan's National Health Insurance (NHI) for eligible breast cancer patients. PhytoHealth continues to build clinical evidence around its proprietary refined Astragalus polysaccharide (rAPS®) platform and explore its broader potential in cancer supportive care. CRF is a debilitating condition distinct from ordinary tiredness and can affect patients throughout cancer treatment. Yet it has historically been underrecognized and undertreated. Beyond developing PG2®, PhytoHealth has worked with Taiwan's medical community to help shift CRF from an often-overlooked aspect of the cancer experience toward a condition that is more actively recognized and managed in clinical care. These efforts contributed to the development of Taiwan's first clinical guidelines for cancer-related fatigue. Building on PG2®'s established clinical use and regulatory foundation in Taiwan, PhytoHealth is actively seeking international pharmaceutical and healthcare partners to advance the global development of PG2® and its botanical drug platform. "This recognition is not only a personal honor, but also a responsibility," Lee said. "Our goal is to turn scientific research into meaningful benefits for patients. We will continue working with medical and industry partners around the world to advance cancer supportive care and bring Taiwan's biotechnology innovation to the global healthcare community." Lee and fellow honorees were recognized for their achievements across professional fields and contributions to society. Lee holds a bachelor's degree in accounting from National Taiwan University and an MBA from Carnegie Mellon University. Before taking on leadership roles in biotechnology, she gained professional experience at Deloitte and Johnson & Johnson's Janssen pharmaceutical business. About PhytoHealth Corporation PhytoHealth Corporation is a Taiwan-based biotechnology company focused on the research, development and commercialization of innovative therapeutics, with particular expertise in botanical drug development. Its portfolio includes PG2 ® Lyo. Injection for cancer-related fatigue and Oraphine ® , an oral analgesic developed for the management of moderate to severe pain. Building on its refined Astragalus polysaccharide (rAPS ® ) platform and broader drug development capabilities, PhytoHealth continues to advance clinical research and pursue international partnerships to bring Taiwan-developed healthcare innovations to global markets. 21% more press release views with Request a Demo

Drug Approval

16 Sep 2024

·www.prnewswire.com

PhytoHealth Corporation announced a new clinical study results published at 2024 ESMO Congress: PG2 plus preoperative chemoradiotherapy improves survival in patients with locally advanced esophageal cancer

TAIPEI and BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- A groundbreaking study conducted by PhytoHealth Corporation, a leading provider of botanical medicine, has revealed that combining Astragalus Polysaccharides (PG2®Lyo. Injection) with standard concurrent chemoradiotherapy (CCRT) significantly improves survival rates for patients with advanced esophageal cancer. The study enrolled 38 patients with stage IIb to IIIb esophageal cancer. Participants were randomly assigned to receive either CCRT alone or CCRT combined with PG2, a proprietary extract of Astragalus membranaceus roots developed by PhytoHealth Corporation. Results showed that patients who received PG2 in addition to CCRT experienced significantly longer overall survival compared to those who received CCRT alone. Furthermore, the combination therapy resulted in a higher tumor objective response rate. The study also found that PG2 helped strengthen the immune system by modulating the tumor immune microenvironment (TIME) and enhancing the suppression of tumor growth. 'These findings offer a new hope for patients with esophageal cancer,'' said Dr. Wen-Chieh Huang, Chief of Division of Thoracic Surgery at Mackay Memorial Hospital, Taiwan and the Principal Investigator of the clinical trial for PG2, a drug for cancer-related fatigue (CRF) relief developed by PhytoHealth Corporation, Taiwan. "PG2 has the potential to become a valuable addition to the standard treatment regimen, and can achieve improved patient outcomes.'' The data will be presented as a poster at the prestigious 2024 ESMO Congress. [ESMO abstract link]. Dr. Huang noted that treatment options for esophageal cancer patients are relatively limited compared to those for other cancers. However, this study has shown that PG2 combination therapy can reduce inflammation markers in the blood, decrease the differentiation of macrophages towards the M2 type, and even help shrink tumors while improving survival rates. This represents a significant breakthrough in the treatment of esophageal cancer. Dr. Huang further added that esophageal cancer patients often face tremendous challenges during treatment, with many unable to complete their therapy. However, by incorporating CRF medication, most patients were able to regain their strength, complete the full courses of cancer treatment, and achieve the expected therapeutic effects. Esophageal cancer is a challenging disease with high recurrence rates and poor survival outcomes. PG2, previously established as a treatment for cancer-related fatigue (already approved by Taiwan Food and Drug Administration) has shown promise as a potential treatment enhancer. This latest discovery marks a significant advancement in the ongoing battle against this challenging cancer. About PhytoHealth Corporation PhytoHealth Corporation is a leader in the development and manufacturing of botanical medicine and natural health products based in Taiwan. With a focus on scientific research and innovation, PhytoHealth is committed to providing safe, effective, and high-quality products that support overall health and well-being. Contact: Alison [email protected] Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

100 Deals associated with Astragalus polysaccharide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Preclinical	China	Affiliated Hospital of Guangdong Medical University	02 May 2025
Cognition Disorders	Preclinical	China	He Bei Zhong Yi Yao Da Xue	02 May 2025
Encephalomyelitis	Preclinical	China	Shanghai University of Traditional Chinese Medicine	01 Dec 2024
Melanoma	Preclinical	China	Shanghai University of Traditional Chinese Medicine	21 Aug 2024
Thrombosis	Preclinical	China	Sun Yat-Sen University	08 Jul 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis